Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | POLB | P06746 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GLS | O94925 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384242 | 0.83 | ALDH1A1 (0.65) | ALDH1A1POLBHTTHPGDLMNA | |
| SCHEMBL602492 | 0.81 | ALDH1A1 (0.69) | ALDH1A1POLBHTTHPGDLMNA | |
| SCHEMBL11749002 | 0.77 | ALDH1A1 (0.53) | ALDH1A1POLBHTTHPGDLMNA | |
| SCHEMBL15472914 | 0.75 | ALDH1A1 (0.61) | ALDH1A1POLBHTTHPGDLMNA | |
| SCHEMBL2644442 | 0.73 | ALDH1A1 (1.00) | ALDH1A1POLBHTTHPGDLMNA | |
| SCHEMBL11750879 | 0.73 | ALDH1A1 (0.56) | ALDH1A1POLBHTTHPGDLMNA | |
| SCHEMBL15884611 | 0.72 | ALDH1A1 (0.70) | ALDH1A1POLBHTTHPGDLMNA | |
| SCHEMBL4220065 | 0.70 | ALDH1A1 (0.69) | ALDH1A1POLBHTTHPGDLMNA | |
| SCHEMBL3027076 | 0.70 | ALDH1A1 (1.00) | ALDH1A1POLBHTTHPGDLMNA | |
| SCHEMBL3467136 | 0.70 | ALDH1A1 (0.63) | ALDH1A1POLBHTTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025066935-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025002360-A1 | MRGPRX2 ANTAGONIST, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-01-02 | — | — | WO | disclosed |
| EP-4055011-A1 | MRGPRX2 ANTAGONISTS AND USES THEREOF | Dermira, Inc (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114728919-A | MrgprX2 antagonists and uses thereof | 德米拉公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-2391611-B1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2391611-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086551-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | ALDH1A1 126/4885POLB 1087/4885HTT 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.